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M A J O R A R T I C L E
Herpes Zoster Risk Factors in a National Cohort
of Veterans with Rheumatoid Arthritis
Jay R. McDonald,1,2 Angelique L. Zeringue,1,2 Liron Caplan,4,5 Prabha Ranganathan,2 Hong Xian,1,2
Thomas E. Burroughs,3 Victoria J. Fraser,2 Fran Cunningham,6 and Seth A. Eisen1,2
1St. Louis Veterans Affairs Medical Center, 2Washington University, and 3St. Louis University, St. Louis, Missouri; 4University of Colorado Health
Sciences Center and 5Denver Veterans Affairs Medical Center, Denver, Colorado; and 6Veterans Affairs Pharmacy Benefits Management, Hines,
Illinois
(See the editorial commentary by Cohen on pages 1372–4)
Background. Herpes zoster occurs more commonly in patients taking immunosuppressive medications, al-
though the risk associated with different medications is poorly understood.
Methods. We conducted a retrospective cohort study involving 20,357 patients who were followed in the
Veterans Affairs healthcare system and treated for rheumatoid arthritis from October 1998 through June 2005.
Cox proportional hazards regression was used to determine risk factors for herpes zoster and herpes zoster–free
survival. Chart review was performed to validate the diagnosis of herpes zoster.
Results. The incidence of herpes zoster was 9.96 episodes per 1000 patient-years. In time-to-event analysis,
patients receiving medications used to treat mild rheumatoid arthritis were less likely to have an episode of herpes
zoster than patients receiving medications used to treat moderate and severe rheumatoid arthritis ( ).P ! .001
Independent risk factors for herpes zoster included older age, prednisone use, medications used to treat moderate
and severe rheumatoid arthritis, malignancy, chronic lung disease, renal failure, and liver disease. Among patients
receiving tumor necrosis factor–a antagonists, etanercept (hazard ratio, 0.62) and adalimumab (hazard ratio, 0.53)
were associated with a lower risk of herpes zoster. There was excellent agreement between the International
Classification of Diseases, Version 9, Clinical Modification diagnosis of herpes zoster and diagnosis by chart review
( ).kp 0.92
Conclusions. Risk factors for herpes zoster included older age, prednisone use, medications used to treat
moderate and severe rheumatoid arthritis, and several comorbid medical conditions. These results demonstrate
that the Department of Veterans Affairs’ national administrative databases can be used to study rare adverse drug
events.
Herpes zoster (HZ), a reactivation of latent varicella-
zoster virus infection, causes substantial morbidity, es-
pecially among elderly and immunocompromised pa-
tients [1]. Established risk factors for HZ include older
age and immunosuppressive medications [2–4]. Other
potential risk factors, including female sex [3, 5, 6],
malignancy [7, 8], kidney disease [6, 8], and AIDS [9],
have been identified by some studies but not others.
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Although it has been established that immunosup-
pressive medications contribute to excess risk of HZ,
the comparative risk of HZ among different immu-
nosuppressive medications is unclear. Enhanced un-
derstanding of the risk of HZ associated with different
classes of immunosuppressive medications may provide
clinicians with useful information as they prescribe im-
munomodulatory drugs to individual patients. This
newfound knowledge may also influence the evaluation
and implementation of HZ immunization strategies in
patients prior to their receipt of immunosuppressive
medications.
Adverse drug events, such as infection after immu-
nosuppression, are between the fourth and sixth most
common cause of death in the United States [10]. Un-
der the Food and Drug Administration’s current drug
approval process, premarketing clinical trials for a new
drug typically include 500–3000 exposed patients. This
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Figure 1. Flow diagram for study of patients in the Veterans Affairs
health care system treated for rheumatoid arthritis, October 1998–June
2005. Data from different discrete time periods within a single patient
record could be included in different medication groups if the patient’s
medication group number increased over time. A patient could be in only
1 medication group at any point in time.
allows identification of common adverse drug events but not
rare ones [11]. Current systems for detection and investigation
of rare adverse drug events in the United States are inadequate
[12]. A 2007 report by the Institute of Medicine emphasized
the need to improve postmarketing surveillance of adverse drug
events by increasing the number and quality of programs that
use data from large automated healthcare databases [13]. The
Department of Veterans Affairs (VA) national administrative
databases present an ideal opportunity to characterize and in-
vestigate rare adverse drug events. In this study, we used the
VA’s national administrative databases to examine HZ risk, risk
factors, treatments, and outcomes in a large national cohort of
veterans with rheumatoid arthritis (RA), with a particular focus
on the contribution of different classes of immunosuppressive
medications to the risk of HZ.
METHODS
This study was approved by the institutional review boards of
the participating institutions.
Databases
The Austin Automation Center is the VA’s centralized repos-
itory of administrative data. We obtained all inpatient and out-
patient International Classification of Diseases, Version 9, Clinical
Modification (ICD-9-CM) diagnosis codes, encounter data, and
demographic data from the inpatient and outpatient data sets
of the Austin Automation Center. We obtained inpatient and
outpatient pharmacy data on our patients from the VA’s Phar-
macy Benefits Management database. Data from the Austin
Automation Center and the Pharmacy Benefits Management
database were merged into a single database by means of com-
mon unique identifiers.
Study Sample
The study period was 1 October 1998–30 June 2005. The study
sample included all veterans who had an ICD-9-CM code di-
agnosis of RA during the study period and who, after a 4-
month history of receiving medications from the VA during
the study period, subsequently received a first prescription for
a disease-modifying antirheumatic drug (DMARD).
We excluded patients who had a diagnosis of HZ at any time
prior to receiving a DMARD or who did not have 2 separate
outpatient or inpatient clinical encounters during the study
period.
Patient records were censored at the end of the last prescribed
medication course, the last clinical encounter, or the first oc-
currence of HZ, whichever came last. Thus, recurrent HZ was
excluded from our analyses. Uncensored patients were followed
up through 31 December 2006.
Definitions
RA. On the basis of an algorithm validated by Singh et al
[14], the diagnosis of RA required both occurrence of an ICD-
9-CM code for RA on 1 occasion in either the inpatient or
outpatient record and the receipt of a prescription for a
DMARD on 1 occasion. See the appendix (online only) for
ICD-9-CM codes accepted for definition of RA.
Medication group. RA treatments were subdivided into
medication groups on the basis of their place in the arma-
mentarium of RA therapeutics. Group 1 (treatment of mild
disease) included hydroxycholoroquine, sulfasalazine, aurano-
fin, injectable gold, and penicillamine. Group 2 (treatment of
moderate disease) included methotrexate, leflunomide, aza-
thioprine, cyclophosphamide, cyclosporine, and anakinra.
Group 3 (treatment of severe disease) included the tumor ne-
crosis factor (TNF)–a antagonists (etanercept, infliximab, and
adalimumab), which are typically used after failure to respond
adequately to medications in groups 1 and 2. Though treatment
of RA is highly individualized, existing RA treatment guidelines
support this classification system [15, 16].
DMARD. DMARDs were defined as all medications in
medication groups 1, 2, and 3.
Patient-time in medication group. Time zero was defined
as the date of the first prescription for a medication in a given
medication group. The patient continued in that medication
group until a medication from a higher-numbered medication
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group was prescribed or until censorship. Data from different
discrete time periods within a single patient record could be
included in different medication groups if the patient’s med-
ication group number increased over time. A patient could be
in only 1 medication group at any point in time.
HZ. The first occurrence in the study period of an ICD-
9-CM code accepted for the definition of HZ (appendix [online
only]) after 1 clinical encounter in the study period without
such an ICD-9-CM code.
Hospitalization for HZ. Hospitalization for which an ICD-
9-CM code for HZ is in the field indicating the diagnosis pri-
marily responsible for hospitalization.
HZ complications. See the appendix (online only) for ac-
cepted ICD-9-CM codes.
HZ treatments. Oral acyclovir, valacyclovir, famciclovir,
and intravenous acyclovir were defined as HZ treatment if they
were prescribed within 90 days before or after HZ diagnosis.
Comorbid medical conditions. We used ICD-9-CM code
definitions developed by Elixhauser et al.17 for use with ad-
ministrative data. Our variable for malignancy was a composite
of ICD-9-CM codes that were used to define metastatic cancer,
solid tumor without metastases, and lymphoma [17].
Validation
The accuracy of ICD-9-CM diagnosis of HZ was measured
against the gold standard, medical record review by a physician.
For the patients in our cohort from the St. Louis VA Medical
Center, medical records were randomly selected for review us-
ing a random number generator. Of 101 patients with an HZ
diagnosis code, 50 were reviewed, and of 3860 patients without
an HZ diagnosis code, 150 were reviewed. Medical record re-
view was performed by 1 author (J.R.M.), by means of a meth-
odology described in the appendix (online only).
Data Analyses
The incidence of HZ was calculated as the number of events
per 1000 patient-years. For descriptive and bivariate analysis,
dichotomous variables were analyzed using the x2 test and
Fisher’s exact test, where appropriate. Continuous variables
were analyzed using the Student’s t test. A 2-sided P value of
!.05 was considered to be statistically significant. The risk of
outcomes was described using hazard ratios and 95% confid-
ence intervals (CIs). Time-to-event analysis was performed us-
ing Cox proportional hazards regression. In regression mod-
eling, membership in each medication group was modeled as
a time-dependent dummy variable to account for the change
in medication groups over time. Each drug was modeled sep-
arately and adjusted for age, sex, race, and time-dependent
comorbid diagnoses. The race variable as it was recorded in
the Austin Automation Center has been shown to correlate
poorly with patient self-report [18]. Despite this limitation, we
obtained this variable and included it in our analyses in order
to control for it. Comorbidities were treated as time-dependent
variables. For validation of the HZ diagnosis, agreement be-
tween ICD-9-CM code and the gold standard was calculated
using the k statistic. All analyses were performed using SAS
software, version 6.12 (SAS Institute). The time-to-event graph
was created using R software, version 2.5.1 (R Foundation).
RESULTS
There were 20,816 patients who met our inclusion criteria. After
applying exclusion criteria, our study cohort consisted of 20,357
patients with 126 million patient-days (figure 1).
Patient demographic characteristics, comorbid medical con-
ditions, and RA treatments are shown in table 1. Of the 20,357
patients, there were 5771 (28.4%) with malignancy; the most
common type of malignancy was prostate cancer (1674 [29%
of malignancies]). The frequency of malignancy in our sample
is consistent with the frequency seen in other administrative
data sets [17], after considering the additional cases found when
outpatient claims data are added [19]. Only 2451 (12.0%) of
the patients had none of the examined comorbid conditions.
There were 713 episodes of HZ in the study cohort, with an
overall incidence of 9.96 episodes per 1000 patient-years. The
incidence of HZ was significantly higher in medication group
2, compared with that of medication group 1 (11.18 vs. 8.00
per 1000 patient-years; ), and the incidence of HZ wasP ! .001
significantly higher in medication group 3, compared with that
of medication group 1 (10.60 vs. 8.00 episodes per 1000 patient-
years; ). The incidence was similar between medicationP ! .001
groups 2 and 3. In time-to-event analysis (figure 2), patients
in each of medication groups 2 and 3 had shorter HZ-free
survival than group 1. HZ-free survival was significantly dif-
ferent between medication groups ( ).P ! .001
In the study cohort, 471 (66.1%) of the 713 patients with
HZ were treated with oral antiviral medications, and 33 (4.6%)
received intravenous acyclovir (table 2). Hospitalization for HZ
occurred in 35 (4.9%) of the patients, and the incidence was
similar between medication groups.
Independent risk factors for HZ included older age, pred-
nisone, medications in groups 2 and 3, malignancy, chronic
lung disease, renal failure, and liver disease (table 3). The hazard
ratio of group 2 medications was similar to the hazard ratio
of group 3 medications (1.34 vs. 1.38; ).Pp .67
There were 96 patients with incident HZ among the 3661
patients who were prescribed TNF antagonists. Of these 96
patients, 59 were receiving etanercept, 33 infliximab, and 4
adalimumab at the time of the HZ episode. Among the TNF
antagonists, etanercept (hazard ratio, 0.62; 95% CI, 0.40–0.95)
and adalimumab (hazard ratio, 0.53; 95% CI, 0.31–0.91) were
associated with a lower risk of HZ, compared with infliximab
(table 4).
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Age, mean (SD) years 62.92 (12.4) 61.9 (12.8) 63.7 (12.0) 59.3 (11.6)
Male sex, no. (%) 18,477 (90.8) 8616 (89.1) 11,764 (91.3) 3333 (91.0)
Race, no. (%)
White 13,639 (67.0) 6311 (65.2) 8696 (67.5) 2565 (70.1)
Black 2280 (11.2) 1320 (13.6) 1299 (10.1) 324 (8.9)
Other 1079 (5.3) 512 (5.3) 651 (5.1) 223 (6.1)
Unknown 3359 (16.5) 1530 (15.8) 2242 (17.4) 549 (15.0)
Medication, % of patients (no. of
months, median [IQR])
Prednisone 59.8 (26 [15–47]) 34.5 (13 [5–30]) 62.7 (18 [6–28]) 55.0 (20 [8–33])
Hydroxychloroquine 46.0 (27 [10–43]) 72.8 (19 [8–38]) 28.7 (19 [7–35]) 22.0 (15 [5–29])
Sulfasalazine 26.8 (14 [5–28]) 39.7 (12 [5–26]) 17.3 (13 [6–26]) 17.0 (12 [5–29])
Auranofin 0.6 (16 [4–28]) 1.0 (14 [5–27]) 0.3 (15 [6–29]) 0.2 (12 [4–26])
Injectable gold 0.4 (13 [6–23]) 0.8 (11 [4–21]) 0.1 (14 [6–22]) 0.2 (11 [7–24])
Penicillamine 0.3 (11 [4–19]) 0.5 (12 [4–21]) 0.1 (10 [5–22]) 0.1 (8 [4–18])
Methotrexate 54.6 (27 [15–48]) 0 83.7 (24 [14–51]) 51.5 (23 [12–52])
Azathioprine 5.1 (13 [4–30]) 0 7.2 (14 [5–26]) 4.9 (13 [4–31])
Leflunomide 13.7 (20 [6–40]) 0 19.8 (18 [5–36]) 19.8 (22 [6–37])
Cyclosporine 1.9 (11 [3–22]) 0 2.7 (13 [4–20]) 1.3 (9 [4–19])
Cyclophosphamide 1.8 (7 [2–13]) 0 2.7 (8 [3–15]) 0.6 (8 [3–13])
Anakinra 0.5 (6 [2–12]) 0 0.5 (7 [2–14]) 1.5 (6 [3–11])
Etanercept 12.4 (16 [6–33]) 0 0 68.9 (16 [6–33])
Infliximab 4.0 (14 [5–30]) 0 0 22.0 (14 [5–30])
Adalimumab 5.8 (9 [4–18]) 0 0 32.4 (9 [4–18])
Comorbidities,a no. (%)
Hypertension 19,284 (94.7) 6949 (71.8) 9634 (74.8) 2701 (73.8)
Diabetes mellitus 7825 (38.4) 2656 (27.5) 4044 (31.4) 1125 (30.7)
Malignancy 5771 (28.3) 2056 (21.3) 2983 (23.1) 732 (20.0)
Chronic lung disease 10,163 (49.9) 3617 (37.4) 5099 (39.6) 1447 (39.5)
Congestive heart failure 3726 (18.3) 1285 (13.3) 1987 (15.4) 454 (12.4)
Cardiac arrhythmia 5408 (26.6) 1804 (18.6) 2871 (22.3) 733 (20.0)
Renal failure 2106 (10.3) 730 (7.5) 1076 (8.3) 300 (8.2)
Liver disease 1582 (7.8) 808 (8.4) 512 (4.0) 262 (7.2)
AIDS 102 (0.5) 46 (0.5) 38 (0.3) 18 (0.5)
None of the above 2451 (12.0) 869 (9.0) 1166 (9.0) 416 (11.4)
Episode of HZ, no. (%) of patients 713 (3.5) 208 (2.2) 409 (3.2) 96 (2.6)
No. of patient-years 71,607.4 25,986.2 36,595.1 9053.5
Episodes of HZ per 1000 patient-years 9.96 8.00 11.18 10.60
NOTE. Because of group switching over time, group sums may exceed total N and statistical comparisons between groups were not performed.
HZ, herpes zoster; IQR, interquartile range.
a Diagnosed prior to or during group time.
A medical record review to validate the ICD-9-CM code for
HZ demonstrated that 45 of the 50 patients with an HZ ICD-
9-CM code had an acute episode of HZ in the 90 days prior
to receiving the code, for a positive predictive value of 90%.
All 5 of the patients who did not have an acute episode of HZ
in the prior 90 days had had HZ in the past. One (0.7%) of
the 150 patients without an HZ ICD-9-CM code had an episode
of acute zoster during the study period, for a negative predictive
value of 99.3%. The k statistic for agreement between the ICD-
9-CM code diagnosis and the medical record diagnosis was
0.92, indicating excellent agreement.
DISCUSSION
For this large sample of patients with RA in the VA health care
system, we analyzed HZ-free survival as well as outcomes, treat-
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Figure 2. Graph of time-to-event analysis indicating herpes zoster (HZ)–free survival for patients in 3 medication groups. After adjusting for
demographic data and comorbid medical conditions, time-to-HZ was different among groups 1, 2, and 3 ( ).P ! .001
ments, and risk factors for HZ. While the occurrence of HZ
in a patient with RA is relatively uncommon, we were able to
identify 713 such occurrences among 20,357 patients, in 171
thousand patient-years, even after applying stringent inclusion
criteria designed to ensure the quality of our data and the
validity of our conclusions. We demonstrated in this population
that the risk of HZ while taking TNF antagonists is similar to
the risk while taking group 2 medications, and that the risk
associated with infliximab exceeds the risk associated with other
TNF antagonists.
HZ incidence was highest among patients taking group 2
and 3 medications, and the risk was similar between the 2
groups. Prior studies have conflicting results in this area. Listing
et al. [20] studied 1529 patients with RA receiving DMARDs
and demonstrated that the risk of herpes virus infections was
similar among patients receiving TNF antagonists and those
receiving other DMARDs. The small study size (only 17 epi-
sodes of HZ were seen) made it unlikely that significant dif-
ferences would be detected. Wolfe et al. [4] studied 10,614
patients with RA and found that cyclophosphamide, azathio-
prine, prednisone, leflunomide, and some nonsteroidal anti-
inflammatory drugs were risk factors for HZ, but that TNF
antagonists and methotrexate were not. However, data on both
medication exposure and HZ incidence were collected by self-
administered patient questionnaires, which are likely to be less
temporally accurate than electronic prescription and diagnosis
data. In addition, our study included more than twice as many
patient-years as this study. Smitten et al. [21] studied a database
of 1160,000 commercially insured patients and found that bi-
ologic DMARDs were associated with a higher risk of HZ than
other DMARDs; however, this study did not differentiate be-
tween groups of nonbiologic DMARDs and did not include
several covariates known to impact HZ risk.
The incidence of HZ in our sample (9.96 episodes per 1000
patient-years) was similar to the incidence seen in other studies.
Donahue et al. [22] and Insinga et al. [23] found incidences
of 2.2 and 3.2 episodes per 1000 patient-years, respectively, in
administrative databases sampling the general US population,
not specifically selected for RA. Studies examining cohorts of
patients with RA found incidences similar to ours: a study using
an administrative database of commercially insured RA patients
in the United States found an incidence of 9.83 episodes per
1000 patient-years [23], and a study using a registry of patients
with RA identified an incidence of 13.2 episodes per 1000 pa-
tient-years [4]. The higher incidence of HZ in the latter study
may be explained by a higher rate of infliximab use among
patients in that study or by overestimates of HZ based on
patient self-report. Although it is possible that inaccuracies in
diagnosis coding explain the difference, our validation results
suggest that our incidence estimate is robust for this population.
We found that older age and certain comorbid medical con-
ditions (malignancy, chronic lung disease, renal failure, and
liver disease) were independent risk factors for HZ. Older age
and cell-mediated immune defects are well-described risk fac-
tors for HZ [2–4]. Prior studies have described malignancy [7,
8], renal disease [6, 8], and chronic lung disease [24] as HZ
risk factors. Female sex was not found to be an HZ risk factor
in our study. Some prior studies have identified female sex as
a risk factor [3, 5, 6], possibly due to sex-specific patterns of
healthcare utilization [24]. Our results may differ because of
the inclusion of previously ignored covariates or differences in
sex-specific healthcare utilization between female veterans and
nonveterans, or because the low proportion of women in our
sample (9.5%) made that part of our analysis relatively
underpowered.
Among patients receiving TNF antagonists, adalimumab and
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Oral 471 (66.1) 136 (65.4) 268 (65.5) 67 (69.8) 1.5 1.1
Intravenous 33 (4.6) 2 (1.0) 28 (6.8) 3 (3.1) !.001a 1.1
HZ complication
HZ meningitis 3 (.4) 1 (0.5) 2 (0.5) 0 (0) 1.1 1.5
Other HZ nervous system complication 136 (19.1) 43 (20.7) 76 (18.6) 17 (17.7) 1.5 1.5
Ophthalmic HZ 48 (6.7) 15 (7.2) 28 (6.8) 5 (5.2) 1.5 1.1
Other HZ complication 45 (6.3) 13 (6.3) 28 (6.8) 4 (4.2) 1.5 1.1
Hospitalization for HZ 35 (4.9) 6 (2.9) 25 (6.1) 4 (4.2) 1.5 1.1
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a Statistically significant association.






(n p 19,644) Hazard ratio (95% CI)
Age, mean (SD) years 63.7 (11.5) 62.9 (12.5) 1.01 (1.01–1.02)a
Male sex 643 (90.2) 17,843 (90.8) 0.79 (0.61–1.02)
Prednisone use 512 (71.8) 12,895 (65.6) 1.41 (1.19–1.67)a
Medication group, no. of patients
Group 1 208 9463 Reference
Group 2 409 12,479 1.34 (1.13–1.59)a
Group 3 96 3565 1.38 (1.08–1.77)a
Hypertension 528 (74.1) 14,928 (76.0) 1.06 (0.89–1.26)
Diabetes mellitus 214 (30.0) 6131 (31.2) 1.03 (0.87–1.21)
Malignancy 173 (24.3) 4742 (24.1) 1.24 (1.04–1.48)a
Chronic lung disease 306 (42.9) 8016 (40.8) 1.28 (1.10–1.49)a
Renal failure 69 (9.7) 1792 (9.1) 1.52 (1.18–1.97)a
Liver disease 46 (6.5) 1293 (6.6) 1.36 (1.00–1.85)a
AIDS 6 (0.8) 83 (0.4) 1.94 (0.87–4.36)a
None of the above 66 (9.3) 1820 (9.3) …
NOTE. Data are no. (%) of patients, unless otherwise indicated. CI, confidence interval; SD, standard
deviation.
a Statistically significant association.
etanercept use were significantly associated with a lower risk
of HZ. This finding is consistent with those of previous studies,
which show higher rates of a composite endpoint of infection
[22] as well as tuberculosis and other granulomatous infections
[25] among patients who received infliximab, compared with
patients who received etanercept. There are several differences
in the properties of TNF antagonists that may explain differ-
ences in infection risk. In contrast to etanercept, infliximab
binds to both soluble and transmembrane forms of TNF, in-
duces apoptosis of monocytes and T cells, and induces ex-
pression of different leukocyte genes [25–27].
This study has significant strengths. The large size and na-
tional scope of this database allows not only the capture of a
large number of rare events but also the application of strict
inclusion criteria to maximize the quality of the data. We lim-
ited our sample to patients with multiple VA clinical encoun-
ters, 4 months of drug prescriptions excluding DMARDs
prior to DMARD initiation, and no HZ diagnosis prior to first
DMARD prescription. Our data spans an 8-year period, allow-
ing for the identification of events that occur long after drug
initiation. Because our patients comprise a real-world cohort
that was not subject to the eligibility criteria often present in
randomized controlled trials of therapeutic agents, our data are
generalizable to similar real-world populations.
Our study is limited by the fact that we did not include
medication dose in our analysis. Duration, however, was taken
1370 • CID 2009:48 (15 May) • McDonald et al.






(n p 3565) Hazard ratio (95% CI)
Age, mean (SD) years 58.5 (12.0) 57.8 (11.7) 1.01 (0.99–1.03)
Male sex 86 (89.6) 3247 (91.1) 0.74 (0.37–1.45)
Medication,a % of patients
(no. of months, median [IQR])
Prednisone 62.5 (10 [4–26]) 54.7 (30 [13–53]) 1.08 (0.69–1.70)
Hydroxychloroquine 16.7 (13 [7–25]) 22.1 (27 [10–45]) 0.70 (0.41–1.21)
Sulfasalazine 8.3 (11 [3–22]) 17.3 (19 [6–42]) 0.44 (0.21–0.91)b
Auranofin 0 0.2 (10 [3–56]) NC
Injectable gold 0 0.3 (17 [10–25]) NC
Penicillamine 0 0.1 (9 [8–37]) NC
Methotrexate 54.2 (12 [6–24]) 51.0 (32 [17–53]) 1.13 (0.75–1.70)
Azathioprine 6.3 (23 [9–42]) 4.8 (11 [3–28]) 1.06 (0.46–2.40)
Leflunomide 21.9 (9 [3–18]) 19.7 (21 [7–41]) 0.95 (0.58–1.56)
Cyclosporine 1.0 (1 [1–1]) 1.3 (7 [2–24]) NC
Cyclophosphamide 1.0 (5 [5–5]) 0.6 (7 [2–14]) NC
Anakinra 1.0 (1 [1–1]) 1.5 (5 [2–13]) NC
Etanercept 64.6 (11 [5–29]) 69.0 (16 [6–33]) 0.62 (0.40–0.95)b
Infliximab 33.3 (8 [3–27]) 21.7 (14 [5–30]) 1.32 (0.85–2.03)
Adalimumab 16.7 (5 [4–10]) 32.8 (9 [4–18]) 0.53 (0.31–0.91)b
Comorbidities
Hypertension 71 (74.0) 2630 (73.8) 1.31 (0.81–2.12)
Diabetes mellitus 30 (31.3) 1095 (30.7) 1.12 (0.71–1.76)
Malignancy 18 (18.8) 714 (20.0) 1.17 (0.69–1.99)
Chronic lung disease 33 (34.4) 1414 (39.7) 0.91 (0.58–1.41)
Renal failure 15 (15.6) 295 (8.3) 0.76 (0.30–1.93)
Liver disease 7 (7.3) 255 (7.2) 1.37 (0.62–3.01)
AIDS 0 (0) 18 (0.5) NC
None of the above 13 (13.5) 403 (11.3)
NOTE. Data are no. (%) of patients, unless otherwise indicated. CI, confidence interval; IQR, interquartile range; NC, not calculated
because of small numbers; SD, standard deviation.
a Received while in medication group 3.
b Statistically significant association.
into account in our survival models. With 14 different
DMARDs plus prednisone in our study, the inclusion of dose
variability in the analysis would have added significant com-
plexity to the interpretation of the study and detracted from
our primary aims. Our population was 190% male, and thus
our results may not be generalizable to a female population.
Although administrative data are imperfect sources of clinical
information, they are very useful for large scale epidemiologic
research. The validity of different ICD-9-CM codes varies
widely [28, 29]. Our validation demonstrates that the diagnosis
of HZ in our data is accurate, and our approach to RA diagnosis
has also been shown to be accurate in prior studies [14].
RA severity can impact risk of infection [30]. We did not
evaluate the impact of RA severity on HZ risk, because there
is no accepted tool for measuring RA severity from adminis-
trative data. One study evaluating the relative contributions of
RA treatment and RA severity to infection risk found that
approximately one-third of the excess risk of infection was
related to RA severity, and two-thirds was related to treatment
[22]. Thus, the excess infection seen in the higher medication
groups was likely caused in part by medication and in part by
RA severity.
A varicella-zoster virus vaccine that prevents HZ is currently
available in the United States and is recommended for use in
individuals who are 60 years of age. Because of the risk of
disseminated disease caused by the live attenuated vaccine strain
of the virus, it is not recommended for patients receiving
higher-dose immunosuppressive therapy, although the Advi-
sory Committee on Immunization Practices has recently ad-
vocated the safety of the vaccine in selected patients receiving
lower-dose corticosteroids and some DMARDs and 14 days
prior to planned immunosuppression [2, 31, 32]. However,
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clinical data supporting these recommendations are sparse, and
our results on the comparative risk of infection among treat-
ment types may inform future efforts to target this vaccine to
populations most likely to benefit.
This study describes the risk of HZ associated with specific
medications used to treat RA. These data may inform clinical
decision-making in prescribing treatment for RA as well as
future HZ vaccine testing and targeting in immunosuppressed
populations. Our data show that the administrative databases
of the Department of Veterans Affairs can be a useful source
of data for the identification and analysis of rare adverse drug
events.
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